Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Dabrafenib

Catalog No: tcsc0692

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg

Specifications

CAS No:
1195765-45-7

Formula:
$C_{23}H_{20}F_3N_5O_2S_2$

Pathway:
MAPK/ERK Pathway

Target:
Raf

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 33 mg/mL (63.52 mM)

Alternative Names:
GSK2118436A;GSK2118436

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Observed Molecular Weight:
519.56

Product Description

Dabrafenib is an ATP-competitive inhibitor of **BRAF** with **IC_{50}**s of 5 nM and 0.6 nM for CRAF and $BRAF^{V600E}$, respectively.

IC50 & Target: IC50: 0.6 nM ($BRAF^{V600E}$), 5 nM (CRAF)[4]

In Vitro: Dabrafenib (GSK2118436, 1 μM) with 0.01 μM GSK1120212 inhibits more than 90% of cell growth in the NRAS mutant clones. GSK2118436 is sufficient to reduce S6P phosphorylation in A375[1]. Dabrafenib suppresses the PolyP-mediated vascular barrier permeability, upregulation of inflammatory biomarkers, adhesion/migration of leukocytes, and activation and/or production of nuclear factor-κB, tumor necrosis factor-α, and interleukin-6[2]. Dabrafenib inhibits the release of HMGB1 and downregulates HMGB1-dependent inflammatory responses by enhancing the expressions of cell adhesion molecules (CAMs) in human endothelial cells[3].

In Vivo: Dabrafenib-treated females have mostly immature reproductive tracts with no evidence of ovulation, similar to age-matched controls; however, DAB-treated females have keratinized and histologically open vaginas[5].